Arvaya Healthcare is acquiring 100% of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.49 crore through a share swap. The company also plans to raise up to ₹210 crore via a Rights Issue.
Arvaya Healthcare Acquires SIGPL, Launches Rights Issue
Arvaya Healthcare Ltd has approved the acquisition of 100% of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.49 crore, using a share swap mechanism. The company is also planning a Rights Issue to raise up to ₹210 crore.
Reader Takeaway: Acquisition expands hospital footprint; rights issue aims for capital infusion.
What just happened
Arvaya Healthcare will acquire SIGPL by issuing 38,71,854 equity shares at ₹40 each. SIGPL has shown consistent turnover growth, reaching ₹6.36 crore in FY24 and projected to reach ₹8.99 crore by FY26. The company is also planning a Rights Issue to raise up to ₹210 crore, with a committee formed to manage its terms. The registered office will also be relocated from Assam to Maharashtra.
Why this matters
The acquisition aims to achieve business synergies, expand the hospital and diagnostic network, and enhance revenue through integrated healthcare services. The capital raised from the Rights Issue will strengthen the balance sheet. This signifies a strategic move towards inorganic growth and expansion for Arvaya Healthcare.
The backstory
SIGPL is a gastroenterology institute. Arvaya Healthcare is pursuing a growth strategy involving the acquisition of established healthcare entities and significant capital raising to fund this expansion.
What changes now
Arvaya Healthcare will integrate SIGPL into its operations, aiming for operational efficiencies and expanded market presence. The Rights Issue, once completed, will provide substantial capital for further growth and strengthening its financial position.
Risks to watch
- Related Party Transaction: Management confirmed Arvaya directors/shareholders are involved with SIGPL, necessitating scrutiny over valuation fairness and potential conflicts of interest.
- Execution Risk: The acquisition requires shareholder approval, and any hurdles could delay or prevent the deal's completion.
- Capital Dilution: The ₹210 crore Rights Issue may dilute existing shareholders' equity if they do not participate.
Peer comparison
While specific peer data is not provided in the filing, Arvaya Healthcare's move to acquire a specialty hospital and raise significant capital positions it for growth within the broader Indian healthcare services sector, which sees ongoing consolidation and expansion.
Context metrics (time-bound)
SIGPL's turnover: ₹6.36 crore (FY24), ₹7.78 crore (FY25), ₹8.99 crore (FY26).
Acquisition consideration: ₹15.49 crore.
Rights Issue target: Up to ₹210 crore.
What to track next
Investors should monitor official disclosures regarding the upcoming Rights Issue, including the record date, entitlement ratio, and pricing. Tracking the integration progress of SIGPL and any further governance updates will also be crucial.